Design, Optimization and Evaluation of Repaglinide Self-Nanoemulsifying Drug Delivery for Enhanced Solubility

DOI:

https://doi.org/10.37285/ijpsn.2017.10.6.8

Authors

  • Mahalaxmi K
  • Sailu Ch

Abstract

The aim of study was to develop self-nanoemulsifying systems of poorly water-soluble drug repaglinide, which is an antidiabetic drug in the class of medications known as meglitinides. Solubility of repaglinide in oily phases and surfactants was determined to identify components of self-nanoemulsifying drug delivery system (SNEDDS). Surfactants and oil was selected based on solubility studies were further screened for their efficiency in formulation. Acrysol K 150, Kolliphor EL and Capmul MCM were selected as oil, surfactant and co-surfactant respectively. Formulation F8 was found to be optimized formulation on the basis of in vitro dissolution studies, particle size and zeta potential. The optimized formulation was then subjected to stability studies and was found to be stable after 6 months. Thus, SNEDDS were found to be influential in improving the release performance of repaglinide, indicating their potential to improve the solubility and oral bioavailability of repaglinide.

 

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Repaglinide, SNEDDS, Zeta potential, Kolliphor-EL, Diabetes mellitus

Downloads

Published

2017-11-30

How to Cite

1.
K M, Ch S. Design, Optimization and Evaluation of Repaglinide Self-Nanoemulsifying Drug Delivery for Enhanced Solubility. Scopus Indexed [Internet]. 2017 Nov. 30 [cited 2024 Dec. 11];10(6):3920-8. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/875

Issue

Section

Research Articles

References

Bhargav P, Upendra P, Bhavin B, Kirtan S, Ghanshyam P and Dhiren Daslaniya (2012). SMEDDS. A Dominant Dosage Form Which Improve Bioavailability., American J of Pharmtech Research 2(4): 58-72.
Culy C and Jarvis B (2001). Repaglinide a review of its therapeutic use in type 2 diabetes mellitus. Drugs 61: 1625-1660
Bhikshapathi D, Madhukar P, Dilip Kumar B and Aravind Kumar G (2013). Formulation and characterization of pioglitazone HCl self-emulsifying drug delivery system. Scholars Research Library 5(2): 292-305.
Desai N S, Bramhane D M and Nagarsenker M S(2011). Repaglinide–cyclodextrin complexes. preparation. characterization and in vivo evaluation of antihyperglycemic activity. J Incl Phenom Macrocycl Chem 70(1-2): 217-225.
Davis S N, Granner D K, Hardman J G and Limbrid L E (2001). oral hypoglycemic agents and the pharmacology of the endocrine pancreas. In. editors. Goodman and Gilman’s the pharmacological basis of therapeutics. USA. McGraw-Hill. 1704-1705.
Gang R and Si-Shen F (2003). Preparation and characterization of poly (lactic acid)-poly (ethylene glycol) microspheres for controlled release of microspheres. Biomaterials. 24: 5037-44 19).
Gupta A K, Mishram D K, and Mahajanm S.C (2011). Preparation and in-vitro evaluation of self-emulsifying drug delivery system of antihypertensive drug valsartan. Int J of Phar & life sci 2: 633-639.
Gursoy R N and Benita S (2004). Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 58: 173-182.
Hauss D J, Fogal S E, Ficorilli J V, Price CA, Roy T, Jayaraj A A and Keirns J J (2007). Oral lipid-based formulations. Adv Drug Deli Rev 59: 667-676.
Shaji J and Jadhav D (2010). Newer approaches to self-emulsifying drug delivery system. Int J of Phar and Pharmaceu Sci 2: 37-41.
Kiran kumar V, M. Aruna devi and D. V. R. N. Bhikshapathi (2013). Development of solid self emulsifying drug delivery systems containing Efavirenz: in vitro and in vivo evaluation: Int J Pharm Bio Sci 4(1): 869-882.
Lawrence M J and Rees G D (2000). Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 45: 89-121
Malaisse W and Repaglinide (1999). A new oral antidiabetic agent: a review of recent preclinical studies. Eur J Clin Invest 29: 21-29.
Mandic Z and Gabelica V (2006). Ionization, lipophilicity and solubility properties of repaglinide. J Pharm Biomed Anal 41(3): 866-871.
Marbury T C, Ruckle J L, Hatorp V, Andersen MP, Nielsen KK, Huang WC and Strange P(2000). Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther 67: 7-15.
Maulik J Patel, Sanjay S Patel, Natvarlal M Patel and Madhabhai M Patel, (2010). A Self-Micro emulsifying Drug Delivery System. 4(3): 29-35.
Purvis T, Mattucci M E, Todd M C, Johnston K P and Williams R O (2007). Rapidly dissolving repaglinide powders produced by the ultra-rapid freezing process. AAPS Pharm Sci Tech 8(3): 52-60.
Seedher N and Kanojia M (2008). Micellar solubilization of some poorly soluble antidiabetic drugs.a technical note. AAPS PharmSciTech 9(2): 431-436.
Shweta G, Sandip C, Krutika K and Sawant (2011.) Self-nanoemulsifying drug delivery system for adefovirdipivoxil. Design characterization in vitro and ex vivo evaluation. Eng Aspects 392: 145- 155
Sinswat P, Matteucci M E, Johnston K P and Williams RO(2007). Dissolution rates and supersaturation behavior of amorphous repaglinide particles produced by controlled precipitation. J Biomed Nanotech 3: 18-27.
Vishvajith A, Kamble, Deepali M, jagdale, Vilasrao J and Kadam (2010). Int J of Pharma and Bio Sci. 2: 25-34.
Zawar L R and Bari SB (2012). Preparation characterization and in vivo evaluation of antihyperglycemic activity of microwave generated repaglinide solid dispersion. Chem Pharm Bull 60(4): 482-487.